Zoster Vaccine Recombinant, Adjuvanted
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)vaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
203 Active assets in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Etoposide Weill Medical College of Cornell University | Phase 2 | BBB |
Lisaftoclax Henan Cancer Hospital | Phase 3 | BBB |
Chlorambucil Ascentage Pharma Group Inc. | Phase 4 | BBB |
Irinotecan IGM Biosciences, Inc. | Phase 2 | BBB |
Prednisone AstraZeneca | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Zoster Vaccine Recombinant, Adjuvanted is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →